DOCSLIB.ORG

Supplement Table 5. Significantly Altered Proteins With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplement Table 5. Significantly Altered Proteins With Supplement Table 5. Significantly altered proteins with Aquamin® (p value <0.05 across all conditions and subjects) Aquamin Proteins Gene 1.5mM 2.1mM 3.0mM 4.5mM Cadherin-17 CDH17 2.834±0.216 2.952±0.600 3.235±0.672 3.616±0.703 Zinc transporter ZIP4 SLC39A4 2.012±0.545 2.077±0.457 2.628±0.769 2.833±0.958 Calcium-activated chloride channel regulator 4 CLCA4 2.029±0.281 2.236±0.506 2.311±0.269 3.006±0.742 Natural resistance-associated macrophage protein 2 SLC11A2 1.911±0.419 2.203±0.427 2.564±0.357 2.683±0.543 Desmoglein-2 DSG2 2.069±0.172 2.104±0.252 2.283±0.367 2.356±0.396 Ly6/PLAUR domain-containing protein 8 LYPD8 2.117±0.215 2.137±0.502 2.459±0.396 2.642±0.927 Sterol 26-hydroxylase, mitochondrial CYP27A1 1.791±0.351 2.018±0.308 2.156±0.416 2.233±0.574 Chloride anion exchanger SLC26A3 1.773±0.291 1.911±0.426 1.889±0.284 2.098±0.385 Carcinoembryonic antigen-related cell adhesion molecule 7 CEACAM7 1.835±0.322 1.998±0.077 2.227±0.372 2.438±0.503 Sodium/glucose cotransporter 1 SLC5A1 1.398±0.161 1.726±0.098 1.940±0.375 2.204±0.283 Tissue alpha-L-fucosidase FUCA1 1.617±0.201 1.812±0.125 1.902±0.270 2.065±0.379 Aminopeptidase N ANPEP 1.909±0.213 2.010±0.247 1.854±0.271 2.002±0.361 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 1.456±0.076 1.776±0.310 1.791±0.320 1.977±0.195 Hydroxymethylglutaryl-CoA synthase, mitochondrial HMGCS2 1.520±0.122 1.742±0.225 1.954±0.222 2.089±0.179 Dehydrogenase/reductase SDR family member 7 DHRS7 1.407±0.176 1.569±0.184 1.683±0.225 1.838±0.316 Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 ENPP3 1.407±0.150 1.598±0.182 1.812±0.194 2.038±0.250 Transmembrane protease serine 2 TMPRSS2 1.532±0.109 1.627±0.196 1.828±0.180 2.077±0.472 Cadherin-related family member 5 CDHR5 1.507±0.143 1.613±0.148 1.768±0.230 1.949±0.478 ATP-binding cassette sub-family G member 2 ABCG2 1.558±0.140 1.761±0.089 1.781±0.142 1.804±0.219 Beta-glucuronidase GUSB 1.287±0.058 1.513±0.228 1.510±0.170 2.002±0.270 Glycogen phosphorylase, brain form PYGB 1.271±0.081 1.412±0.182 1.577±0.225 1.667±0.270 Fucose mutarotase FUOM 1.436±0.133 1.759±0.253 1.832±0.186 2.041±0.575 Solute carrier family 15 member 1 SLC15A1 1.556±0.094 1.675±0.138 1.725±0.147 1.806±0.361 Multidrug resistance protein 1 ABCB1 1.297±0.032 1.451±0.039 1.547±0.091 1.698±0.216 Junction plakoglobin JUP 1.597±0.176 1.712±0.118 1.768±0.130 1.774±0.111 P2X purinoceptor 4 P2RX4 1.411±0.135 1.516±0.167 1.567±0.130 1.630±0.267 Long-chain-fatty-acid--CoA ligase 5 ACSL5 1.369±0.155 1.451±0.165 1.582±0.202 1.649±0.297 Hephaestin HEPH 1.501±0.173 1.647±0.280 1.830±0.261 1.833±0.264 Amine oxidase [flavin-containing] A MAOA 1.344±0.135 1.457±0.156 1.475±0.174 1.580±0.262 Sulfotransferase family cytosolic 1B member 1 SULT1B1 1.533±0.184 1.585±0.199 1.680±0.124 1.736±0.367 Beta-galactosidase GLB1 1.321±0.066 1.462±0.087 1.581±0.171 1.619±0.180 Peroxiredoxin-like 2A FAM213A 1.296±0.062 1.469±0.142 1.527±0.138 1.597±0.184 Beta-hexosaminidase subunit beta HEXB 1.296±0.027 1.365±0.066 1.486±0.129 1.554±0.169 Peroxisomal acyl-coenzyme A oxidase 2 ACOX2 1.316±0.037 1.418±0.092 1.490±0.128 1.564±0.188 Guanine nucleotide-binding protein subunit alpha-11 GNA11 1.302±0.067 1.439±0.150 1.562±0.251 1.57±0.210 Superoxide dismutase, mitochondrial SOD2 1.272±0.106 1.427±0.141 1.418±0.065 1.556±0.007 Unconventional myosin-VIIb MYO7B 1.259±0.024 1.371±0.100 1.465±0.133 1.476±0.158 Gelsolin GSN 1.218±0.065 1.231±0.072 1.360±0.088 1.478±0.175 Ectonucleoside triphosphate diphosphohydrolase 8 ENTPD8 1.489±0.061 1.455±0.119 1.509±0.076 1.608±0.144 Inositol 1,4,5-trisphosphate receptor type 3 ITPR3 1.244±0.055 1.359±0.124 1.442±0.121 1.450±0.130 Diphosphoinositol polyphosphate phosphohydrolase 2 NUDT4 1.216±0.057 1.301±0.092 1.437±0.043 1.587±0.208 Ubiquitin-like protein 3 UBL3 1.320±0.056 1.456±0.078 1.491±0.076 1.502±0.182 Plectin PLEC 1.273±0.096 1.454±0.077 1.434±0.142 1.506±0.027 Serotransferrin TF 1.375±0.034 1.442±0.160 1.497±0.219 1.568±0.271 Peroxisomal acyl-coenzyme A oxidase 1 ACOX1 1.252±0.093 1.243±0.091 1.373±0.082 1.457±0.081 Lysosomal alpha-glucosidase GAA 1.256±0.035 1.314±0.036 1.460±0.029 1.492±0.043 Keratin, type II cytoskeletal 8 KRT8 1.250±0.098 1.524±0.092 1.433±0.037 1.488±0.103 Very-long-chain 3-oxoacyl-CoA reductase HSD17B12 1.284±0.014 1.418±0.135 1.532±0.110 1.533±0.142 Alpha-methylacyl-CoA racemase AMACR 1.269±0.050 1.439±0.024 1.428±0.032 1.419±0.076 Ectonucleoside triphosphate diphosphohydrolase 5 ENTPD5 1.257±0.095 1.336±0.041 1.342±0.092 1.387±0.153 Desmocollin-2 DSC2 1.386±0.072 1.345±0.109 1.385±0.134 1.427±0.123 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2 1.186±0.070 1.288±0.125 1.406±0.055 1.429±0.062 Cytosolic 10-formyltetrahydrofolate dehydrogenase ALDH1L1 1.143±0.054 1.210±0.051 1.318±0.088 1.376±0.127 Pituitary tumor-transforming gene 1 protein PTTG1IP 1.325±0.069 1.225±0.052 1.375±0.022 1.399±0.166 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial ACADM 1.164±0.058 1.309±0.039 1.323±0.066 1.362±0.136 UDP-glucuronosyltransferase 1-10 UGT1A10 1.298±0.131 1.327±0.143 1.388±0.033 1.394±0.138 Chloride intracellular channel protein 3 CLIC3 1.373±0.143 1.328±0.135 1.504±0.199 1.500±0.240 Major vault protein MVP 1.205±0.087 1.283±0.093 1.319±0.086 1.393±0.169 Lysosome membrane protein 2 SCARB2 1.261±0.084 1.295±0.123 1.366±0.149 1.384±0.120 Carnitine O-palmitoyltransferase 1, liver isoform CPT1A 1.196±0.078 1.278±0.062 1.353±0.102 1.360±0.145 Calcium-binding mitochondrial carrier protein Aralar2 SLC25A13 1.152±0.058 1.288±0.093 1.320±0.110 1.380±0.133 Acid sphingomyelinase-like phosphodiesterase 3a SMPDL3A 1.411±0.102 1.356±0.137 1.356±0.014 1.327±0.130 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 LPGAT1 1.174±0.045 1.263±0.090 1.304±0.022 1.331±0.105 Xanthine dehydrogenase/oxidase XDH 1.267±0.039 1.345±0.082 1.384±0.052 1.403±0.059 Phytanoyl-CoA dioxygenase, peroxisomal PHYH 1.119±0.025 1.275±0.115 1.321±0.068 1.357±0.127 Sigma intracellular receptor 2 TMEM97 1.304±0.120 1.484±0.123 1.396±0.090 1.325±0.124 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial ACADVL 1.143±0.050 1.326±0.046 1.363±0.052 1.375±0.051 Phosphatidate cytidylyltransferase 1 CDS1 1.126±0.014 1.283±0.121 1.271±0.090 1.309±0.091 Pyruvate carboxylase, mitochondrial PC 1.290±0.031 1.331±0.155 1.360±0.162 1.345±0.134 Unconventional myosin-XVB MYO15B 1.257±0.093 1.246±0.068 1.322±0.011 1.344±0.133 Protein phosphatase 1 regulatory subunit 3G PPP1R3G 1.239±0.035 1.265±0.046 1.394±0.187 1.325±0.114 DnaJ homolog subfamily A member 4 DNAJA4 1.254±0.107 1.212±0.066 1.336±0.041 1.401±0.138 Procollagen lysine hydroxylase and glycosyltransferase LH3 PLOD3 1.147±0.047 1.193±0.047 1.294±0.097 1.334±0.111 Thiosulfate sulfurtransferase TST 1.209±0.013 1.273±0.111 1.357±0.112 1.420±0.203 ATP-dependent 6-phosphofructokinase, liver type PFKL 1.143±0.044 1.193±0.082 1.278±0.110 1.276±0.083 Polypeptide N-acetylgalactosaminyltransferase 12 GALNT12 1.196±0.060 1.266±0.089 1.297±0.089 1.287±0.112 Carboxylesterase 3 CES3 1.240±0.101 1.313±0.043 1.245±0.030 1.311±0.120 Serine beta-lactamase-like protein LACTB, mitochondrial LACTB 1.176±0.049 1.307±0.105 1.288±0.034 1.313±0.026 Basement membrane-specific heparan sulfate proteoglycan protein HSPG2 1.131±0.013 1.227±0.040 1.237±0.050 1.316±0.104 Maestro heat-like repeat-containing protein family member 1 MROH1 1.135±0.027 1.315±0.022 1.354±0.060 1.331±0.092 ATP-binding cassette sub-family D member 3 ABCD3 1.176±0.046 1.306±0.138 1.357±0.095 1.307±0.076 Mitochondrial proton/calcium exchanger protein LETM1 1.140±0.050 1.173±0.069 1.211±0.085 1.251±0.097 Aldose 1-epimerase GALM 1.157±0.052 1.169±0.046 1.262±0.084 1.294±0.049 Aldehyde dehydrogenase, mitochondrial ALDH2 1.167±0.031 1.240±0.016 1.252±0.037 1.282±0.063 IST1 homolog IST1 1.187±0.004 1.127±0.030 1.243±0.035 1.261±0.115 Acyl-coenzyme A thioesterase 1 ACOT1 1.162±0.037 1.239±0.022 1.248±0.012 1.238±0.047 2,4-dienoyl-CoA reductase, mitochondrial DECR1 1.120±0.029 1.127±0.017 1.177±0.008 1.216±0.079 Serpin H1 SERPINH1 1.132±0.028 1.192±0.027 1.192±0.061 1.228±0.042 Protein mono-ADP-ribosyltransferase PARP4 PARP4 1.173±0.024 1.178±0.014 1.235±0.047 1.273±0.104 Peroxisomal acyl-coenzyme A oxidase 3 ACOX3 1.168±0.049 1.193±0.019 1.247±0.038 1.206±0.024 StAR-related lipid transfer protein 5 STARD5 1.204±0.065 1.221±0.091 1.297±0.089 1.221±0.094 MAGUK p55 subfamily member 7 MPP7 1.052±0.017 1.146±0.047 1.108±0.018 1.183±0.052 Methylglutaconyl-CoA hydratase, mitochondrial AUH 1.162±0.038 1.246±0.006 1.282±0.062 1.241±0.092 Farnesyl pyrophosphate synthase FDPS 1.137±0.013 1.242±0.088 1.241±0.068 1.229±0.087 Catechol O-methyltransferase domain-containing protein 1 COMTD1 1.208±0.026 1.265±0.063 1.216±0.036 1.215±0.068 Glycogen debranching enzyme AGL 1.088±0.026 1.121±0.045 1.137±0.035 1.171±0.033 Succinate dehydrogenase [ubiquinone] flavoprotein, mitochondrial SDHA 1.073±0.003 1.124±0.051 1.171±0.042 1.176±0.066 Neuroplastin NPTN 1.155±0.013 1.140±0.012 1.144±0.008 1.181±0.065 Vinculin VCL 1.095±0.015 1.237±0.065 1.178±0.060 1.188±0.049 Villin-1 VIL1 1.092±0.025 1.123±0.035 1.142±0.014 1.144±0.051 Disintegrin and metalloproteinase domain-containing protein 9 ADAM9 0.903±0.036 0.872±0.020 0.916±0.007 0.899±0.028 Aspartate--tRNA ligase, mitochondrial DARS2 0.949±0.017 0.906±0.011 0.880±0.018 0.875±0.029 E3 ubiquitin-protein ligase HUWE1 HUWE1 0.919±0.030 0.900±0.026 0.903±0.019 0.862±0.044 Integrin alpha-3 ITGA3 0.919±0.027 0.903±0.028 0.859±0.010 0.868±0.035 Talin-1 TLN1 0.919±0.012 0.892±0.016 0.881±0.020 0.867±0.050 Nuclear pore complex protein Nup155 NUP155 0.832±0.011
Load more

Recommended publications
  • United States Patent 19 11 Patent Number: 5,780,253 Subramanian Et Al
    III USOO5780253A United States Patent 19 11 Patent Number: 5,780,253 Subramanian et al. (45) Date of Patent: Jul. 14, 1998 54 SCREENING METHOD FOR DETECTION OF 4.433.999 2/1984 Hyzak ....................................... 71.03 HERBCDES 4.6–552 2/1987 Anoti et al. if O3. 4,802,912 2/1989 Baker ........................................ 7/103 Inventors: Wenkiteswaran Subramanian Danville: Anne G. Toschi. Burlingame. OTHERTHER PPUBLICATION CATIONS both of Calif. Heim et al. Pesticide Biochem & Physiol; vol. 53, pp. 138-145 (1995). 73) Assignee: Sandoz Ltd., Basel. Switzerland Hatch. MD.: Phytochem. vol. 6... pp. 115 to 119, (1967). Haworth et al. J. Agric. Food Chem, vol. 38, pp. 1271-1273. 21 Appl. No.:752.990 1990. Nishimura et al: Phytochem: vol. 34, pp. 613-615. (1993). 22 Filed: Nov. 21, 1996 Primary Examiner-Louise N. Leary Related U.S. Application Data Attorney, Agent, or Firm-Lynn Marcus-Wyner: Michael P. Morris 63 Continuation of Ser. No. 434.826, May 4, 1995, abandoned. 6 57 ABSTRACT 51 Int. Cl. ............................... C12Q 1/48: C12Q 1/32: C12Q 1/37; C12O 1/00 This invention relates to novel screening methods for iden 52 U.S. Cl. ................................. 435/15:435/18: 435/26: tifying compounds that specifically inhibit a biosynthetic 435/23: 435/4, 536/23.6:536/23.2:536/24.3 pathway in plants. Enzymes which are specifically affected 536/26.11:536/26.12:536/26.13 by the novel screening method include plant purine biosyn 58 Field of Search .................................. 435/15, 8, 26, thetic pathway enzymes and particularly the enzymes 435/23 4: 536/23.6, 23.2, 24.3, 26.1, involved in the conversion of inosine monophosphate to 26.12, 26.13 adenosine monophosphate and inosine monophosphate to guanosine monophosphate.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Complete Genome of the Cellyloytic Thermophile Acidothermus Cellulolyticus 11B Provides Insights Into Its Ecophysiological and Evloutionary Adaptations
    Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory Title Complete genome of the cellyloytic thermophile Acidothermus cellulolyticus 11B provides insights into its ecophysiological and evloutionary adaptations Permalink https://escholarship.org/uc/item/5xg662d7 Author Barabote, Ravi D. Publication Date 2009-08-25 eScholarship.org Powered by the California Digital Library University of California Title: Complete genome of the cellyloytic thermophile Acidothermus cellulolyticus 11B provides insights into its ecophysiological and evolutionary adaptations Author(s): R. Barabote1,†, G. Xie1, D. Leu2, P. Normand3, A. Necsulea4, V. Daubin4, C. Médigue5, W. Adney6, X. Xu2, A. Lapidus7, C. Detter1, P. Pujic3, D. Bruce1, C. Lavire3, J. Challacombe1, T. Brettin1 and Alison M. Berry2. Author Affiliations: 1 DOE Joint Genome Institute, Bioscience Division, Los Alamos National Laboratory, 2 Department of Plant Sciences, University of California, Davis, 3 Centre National de la Recherche Scientifique (CNRS), UMR5557, Écologie Microbienne, Université Lyon I, Villeurbanne, 4 Centre National de la Recherche Scientifique (CNRS), UMR5558, Laboratoire de Biométrie et Biologie Évolutive, Université Lyon I, Villeurbanne, 5 Centre National de la Recherche Scientifique (CNRS), UMR8030 and CEA/DSV/IG/Genoscope, Laboratoire de Génomique Comparative, 6 National Renewable Energy Laboratory 7 DOE Joint Genome Institute Date: 06/10/09 Funding: This work was performed under the auspices of the US Department of Energy's Office of Science, Biological and Environmental Research Program, and by the University of California, Lawrence Berkeley National Laboratory under contract No. DE-AC02- 05CH11231, Lawrence Livermore National Laboratory under Contract No. DE-AC52-07NA27344, and Los Alamos National Laboratory under contract No. DE-AC02-06NA25396. R. D. Barabote Complete genome of the cellulolytic thermophile Acidothermus cellulolyticus 11B provides insights into its ecophysiological and evolutionary adaptations.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Classical and Rational Approaches to Antifungal Drug Design
    Classical and rational approaches to antifungal drug design Jessica Louise Chitty BSc (Hons) A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2017 School of Chemistry and Molecular Biosciences Institute of Molecular Biosciences Abstract The emergence of human immunodeficiency virus (HIV) in the 1980s has led to an increase in infections from previously rare pathogens. Many of these now cause widespread infection among individuals with compromised immune systems, not just limited to AIDS patients but also to those placed on immunosuppressive medication. The encapsulated yeast Cryptococcus neoformans causes widespread disease in the immunocompromised population, particularly in sub-Saharan Africa where it is a major cause of AIDS-related mortality due in part to limited resources and variable drug availability. Current treatment options are restricted to three out-dated antifungals amphotericin B, flucytosine and fluconazole; where possible they are used in combination as nephrotoxicity and resistance are contributing factors in the unacceptably high mortality rates. Alternative therapeutic agents are urgently required to improve survival rates and combat antifungal drug resistance. Two main routes of compound development can be taken: classical drug screening or rational drug design. Classical design requires groups of compounds to be screened against pathogens and those identified with high efficacy and low cytotoxicity are pursued. Rational drug design requires a detailed characterization of the proposed target; exploitable differences between the pathogen and human host are sought out as potential druggable targets. In this thesis both classical and rational methods have been investigated. A classical approach was taken to investigate a class of octapeptin compounds, produced as secondary metabolites by the soil dwelling bacterium, Bacillus circulans.
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • Proteomics Analysis of Colon Cancer Progression
    Saleem et al. Clin Proteom (2019) 16:44 https://doi.org/10.1186/s12014-019-9264-y Clinical Proteomics RESEARCH Open Access Proteomics analysis of colon cancer progression Saira Saleem1* , Sahrish Tariq1, Ifat Aleem1, Sadr‑ul Shaheed2, Muhammad Tahseen3, Aribah Atiq3, Sadia Hassan4, Muhammad Abu Bakar5, Shahid Khattak6, Aamir Ali Syed6, Asad Hayat Ahmad3, Mudassar Hussain3, Muhammed Aasim Yusuf7 and Chris Sutton2 Abstract Background: The aim of this pilot study was to identify proteins associated with advancement of colon cancer (CC). Methods: A quantitative proteomics approach was used to determine the global changes in the proteome of pri‑ mary colon cancer from patients with non‑cancer normal colon (NC), non‑adenomatous colon polyp (NAP), non‑met‑ astatic tumor (CC NM) and metastatic tumor (CC M) tissues, to identify up‑ and down‑regulated proteins. Total protein was extracted from each biopsy, trypsin‑digested, iTRAQ‑labeled and the resulting peptides separated using strong cation exchange (SCX) and reverse‑phase (RP) chromatography on‑line to electrospray ionization mass spectrometry (ESI‑MS). Results: Database searching of the MS/MS data resulted in the identifcation of 2777 proteins which were clustered into groups associated with disease progression. Proteins which were changed in all disease stages including benign, and hence indicative of the earliest molecular perturbations, were strongly associated with spliceosomal activity, cell cycle division, and stromal and cytoskeleton disruption refecting increased proliferation and expansion into the surrounding healthy tissue. Those proteins changed in cancer stages but not in benign, were linked to infammation/ immune response, loss of cell adhesion, mitochondrial function and autophagy, demonstrating early evidence of cells within the nutrient‑poor solid mass either undergoing cell death or adjusting for survival.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • New Mechanisms That Regulate the Expression of Genes Implicated in the Process of Ketogenesis
    Isabel Alexandra Pinto Carrilho do Rosário Licenciatura em Bioquímica New mechanisms that regulate the expression of genes implicated in the process of ketogenesis Dissertação para obtenção do Grau de Mestre em Biotecnologia Orientador: Prof. Dr. Pedro F. Marrero González, Prof. Titular, Facultat de Farmàcia, Universitat de Barcelona Co-orientador: Prof. Dr. Diego Haro Bautista, Prof. Catedrático, Facultat de Farmàcia, Universitat de Barcelona Presidente: Prof. Doutora Isabel Maria Godinho de Sá Nogueira Arguente: Prof. Doutor Pedro Miguel Ribeiro Viana Baptista Setembro, 2012 Isabel Alexandra Pinto Carrilho do Rosário Licenciatura em Bioquímica New mechanisms that regulate the expression of genes implicated in the process of ketogenesis Dissertação para obtenção do Grau de Mestre em Biotecnologia Orientador: Prof. Dr. Pedro F. Marrero González, Prof. Titular, Facultat de Farmàcia, Universitat de Barcelona Co-orientador: Prof. Dr. Diego Haro Bautista, Prof. Catedrático, Facultat de Farmàcia, Universitat de Barcelona Setembro, 2012 Copyright New mechanisms that regulate the expression of genes implicated in the process of ketogenesis © Isabel Alexandra Pinto Carrilho do Rosário FCT/UNL UNL A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição, com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. i ii Ninguém sabe que coisa quer. Ninguém conhece que alma tem, Nem o que é mal nem o que o bem.
    [Show full text]
  • Murine Neonatal Ketogenesis Preserves Mitochondrial Energetics by Preventing Protein Hyperacetylation
    ARTICLES https://doi.org/10.1038/s42255-021-00342-6 Murine neonatal ketogenesis preserves mitochondrial energetics by preventing protein hyperacetylation Yuichiro Arima 1,2,13 ✉ , Yoshiko Nakagawa3,13, Toru Takeo 3,13, Toshifumi Ishida 1, Toshihiro Yamada1, Shinjiro Hino4, Mitsuyoshi Nakao4, Sanshiro Hanada 2, Terumasa Umemoto 2, Toshio Suda2, Tetsushi Sakuma 5, Takashi Yamamoto5, Takehisa Watanabe6, Katsuya Nagaoka6, Yasuhito Tanaka6, Yumiko K. Kawamura7,8, Kazuo Tonami7, Hiroki Kurihara7, Yoshifumi Sato9, Kazuya Yamagata9,10, Taishi Nakamura 1,11, Satoshi Araki1, Eiichiro Yamamoto1, Yasuhiro Izumiya1,12, Kenji Sakamoto1, Koichi Kaikita1, Kenichi Matsushita 1, Koichi Nishiyama2, Naomi Nakagata3 and Kenichi Tsujita1,10 Ketone bodies are generated in the liver and allow for the maintenance of systemic caloric and energy homeostasis during fasting and caloric restriction. It has previously been demonstrated that neonatal ketogenesis is activated independently of starvation. However, the role of ketogenesis during the perinatal period remains unclear. Here, we show that neonatal ketogen- esis plays a protective role in mitochondrial function. We generated a mouse model of insufficient ketogenesis by disrupting the rate-limiting hydroxymethylglutaryl-CoA synthase 2 enzyme gene (Hmgcs2). Hmgcs2 knockout (KO) neonates develop microvesicular steatosis within a few days of birth. Electron microscopic analysis and metabolite profiling indicate a restricted energy production capacity and accumulation of acetyl-CoA in Hmgcs2 KO mice. Furthermore,
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]